Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of youth utilizing pediatric dermatology: A cross-sectional PEDSnet study.

Journal of the American Academy of Dermatology·2025
Same author

Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.

JAMA dermatology·2025
Same author

Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.

Pediatric dermatology·2025
Same author

Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

Dermatology and therapy·2025
Same author

Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry.

American journal of clinical dermatology·2025

Related Experiment Video

Updated: May 31, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Systemic therapies for atopic dermatitis.

Rame Yousif1, Dareen Elgindi1, Amy S Paller2

  • 1Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Journal of the American Academy of Dermatology
|May 28, 2026
PubMed
Summary
This summary is machine-generated.

Advanced systemic therapies, including biologics and oral Janus kinase inhibitors (JAKis), offer new hope for moderate-to-severe atopic dermatitis. These treatments target key pathways to manage eczema and improve patient quality of life.

Keywords:
Janus Kinase inhibitoratopic dermatitisbiologicsdupilumabpediatric dermatology

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Related Experiment Videos

Last Updated: May 31, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis is a chronic, relapsing skin condition causing significant pruritus and reduced quality of life.
  • Moderate-to-severe atopic dermatitis significantly impacts patients' well-being.
  • Current treatment landscape includes traditional therapies and emerging advanced systemic options.

Purpose of the Study:

  • To review advanced systemic therapies for moderate-to-severe atopic dermatitis.
  • To discuss practical considerations for selecting appropriate therapies.
  • To highlight key agents including biologics and oral Janus kinase inhibitors (JAKis).

Main Methods:

  • Literature review of advanced systemic agents for atopic dermatitis.
  • Analysis of approved biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and oral JAKis (upadacitinib, abrocitinib, baricitinib).
  • Discussion of therapeutic mechanisms, efficacy, and safety considerations.

Main Results:

  • Injectable biologics like dupilumab target interleukin-4 receptors and are approved for patients from 6 months, also improving comorbid allergic conditions.
  • Other biologics (tralokinumab, lebrikizumab targeting IL-13) and an IL-31 receptor inhibitor (nemolizumab) are approved for adolescents and adults.
  • Oral JAKis provide rapid relief of pruritus and inflammation but require careful safety consideration.

Conclusions:

  • Advanced systemic therapies have transformed atopic dermatitis management.
  • Biologics and JAKis offer distinct mechanisms and patient profiles.
  • Therapy selection requires balancing efficacy, safety, and patient-specific factors.